 For women in the general population, randomized controlled trials have shown that adjuvant tamoxifen treatment after a first breast cancer (BC) diagnosis halves the risk of contralateral breast cancer (CBC).  It is uncertain if tamoxifen has any efficacy for women carrying mutations in BRCA1 or BRCA2, and it is not commonly prescribed to carriers for the purpose of BC prevention.
OBJECTIVE:
 To determine whether adjuvant tamoxifen treatment for BC is associated with reduced CBC risk for BRCA1 and/or BRCA2 mutation carriers and whether the strength of association differs according to the estrogen receptor (ER) status of the first BC
METHODS:
 Design: observational, retrospective and prospective cohort  Inclusion criteria: pathogenic mutation in BRCA1 or BRCA2, BC diagnosed since 1970 that was not bilateral at the time of diagnosis (within 6 months of first diagnosis)  Exclusion criteria: history of invasive cancers or tamoxifen use before first BC  Enrolled: 2,464 women (1,583 BRCA1 and 881 BRCA2 mutation carriers) were included in combined retrospective (before cohort entry) and prospective (after cohort entry) follow-up analysis; 1,083 women (657 BRCA1 and 426 BRCA2 mutation carriers) were included in prospective follow-up only analysis  Drug regimens: women were considered to have used tamoxifen if they took it for any period of time after their first BC diagnosis (dosages/durations not reported)  Outcome measure: hazard ratios for CBC associated with tamoxifen use after first BC for BRCA1 and BRCA2 mutation carriers  Power: not calculated; post-hoc power for prospective data analysis: 80% at p <.05 to detect HRs of ≤0.35
RESULTS:
 Median time since first BC diagnosis was 6.6 years; median time since cohort entry was 3. 
STRENGTHS:
 Multi-nation study; study results could be extrapolated to a large population  Appropriate statistical tests utilized  Multivariate analyses and sensitivity analyses were conducted  Results were reported for each outcome measure LIMITATIONS:
 Relatively weak study design  Inclusion/exclusion criteria did not address specific chemotherapy agents or radiation therapy that could affect results  Power was not calculated prior to the investigation; post-hoc power was not sufficient for outcome measures using prospective data only; therefore, Type II error is possible  Unknown what dosage and duration of tamoxifen therapy patients received on average, or if treatment was comparable between cohorts  Significant potential for treatment variation since multiple countries and many years involved  Primary and secondary outcome measures were not clearly defined  Standardization and training did not occur among various investigators involved  Questionnaires and frequency of follow-up varied between cohorts  Data were self-reported by study participants  Relatively short follow-up time after first BC diagnosis  Prospective data only available for 44% of women  Retrospective data analysis would have the potential to produce biased results  Prospective data analysis excluded prevalent cancer cases  Analysis by ER status of first BC was unclear  Many baseline differences between tamoxifen users and nonusers could have affected results  Compliance and adverse effects were not assessed CONCLUSION:
 Tamoxifen may reduce the risk of CBC for BRCA1 and BRCA2 mutation carriers. However, this study had many limitations so extrapolation of results should be conservative.  For women with BRCA1 and BRCA2 mutations, bilateral mastectomy and premenopausal bilateral salpingo-oophorectomy are associated with a reduced BC risk of >90% and approximately 50%, respectively. Further research with tamoxifen use for CBC prevention may support this drug as a noninvasive alternative for women with BRCA1 or BRCA2 mutations.  Further investigation is required. A randomized, controlled experimental study would be ideal. Further research should focus on BRCA mutation carries with ER-negative BC, as adjuvant endocrine therapy is already the standard of care for treatment of ER-positive BC regardless of BRCA mutation status. 
